These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32974126)

  • 1. Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055).
    Li M; Hou X; Zhou C; Feng W; Jiang G; Long H; Yang S; Chen J; Wang N; Wang K; Chen L
    Front Oncol; 2020; 10():1216. PubMed ID: 32974126
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
    Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.
    Lei YY; Yang JJ; Zhang XC; Zhong WZ; Zhou Q; Tu HY; Tian HX; Guo WB; Yang LL; Yan HH; Chen HJ; Xie Z; Su J; Han JF; Wu YL
    Clin Lung Cancer; 2016 May; 17(3):223-31. PubMed ID: 26454342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant mutation status of
    Li J; Zhang B; Zhang Y; Xu F; Zhang Z; Shao L; Yan C; Ulivi P; Denis MG; Christopoulos P; Thomas de Montpréville V; Bernicker EH; van der Wekken AJ; Wang C; Yue D
    Transl Lung Cancer Res; 2021 Mar; 10(3):1525-1535. PubMed ID: 33889527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
    Tao H; Shi L; Zhou A; Li H; Gai F; Huang Z; Che N; Liu Z
    Lung Cancer; 2020 Nov; 149():154-161. PubMed ID: 33017727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061).
    Li M; Hou X; Chen J; Zhang B; Wang N; Han H; Chen L
    Lung Cancer; 2022 Mar; 165():54-62. PubMed ID: 35091210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib.
    Liang H; Ma D; Xu Y; Zhao J; Chen M; Liu X; Zhong W; Li J; Wang M
    Cancer Manag Res; 2019; 11():8191-8200. PubMed ID: 31564978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.
    Zhang B; Zhang Y; Xu J; Zhang X; Chu T; Wang S; Qian J; Qiao R; Lu J; Zhang L; Han B
    Target Oncol; 2018 Oct; 13(5):631-639. PubMed ID: 30218431
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Wang WX; Xu CW; Chen YP; Liu W; Zhong LH; Chen FF; Zhuang W; Huang YJ; Huang ZZ; Chen RR; Guan YF; Yi X; Lv TF; Zhu WF; Lu JP; Wang XJ; Shi Y; Lin XD; Chen G; Song Y
    J Thorac Dis; 2018 May; 10(5):2991-2998. PubMed ID: 29997966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
    Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
    J Clin Oncol; 2016 Oct; 34(28):3383-9. PubMed ID: 27354483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
    Wang W; Sun X; Hui Z
    Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.
    Zhang L; Li Y; Zhang S; Gao C; Nie K; Ji Y
    Cancer Biol Med; 2018 May; 15(2):178-181. PubMed ID: 29951342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer.
    Lin YT; Liu YN; Shih JY
    Front Oncol; 2019; 9():880. PubMed ID: 31608224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report.
    Wu X; Zhou H; He Z; Zhang Z; Feng W; Zhao J; Chen H; Wang S; Wang W; Wang Q
    Transl Lung Cancer Res; 2020 Dec; 9(6):2494-2499. PubMed ID: 33489809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.